Literature DB >> 9861237

Pure red cell aplasia and myasthenia gravis with thymoma: a case report and review of the literature.

S Mizobuchi1, T Yamashiro, Y Nonami, A Yamamoto, M Kume, H Nakaya, T Sawada, H Taguchi, T Moriki, S Ogoshi.   

Abstract

A case of pure red cell aplasia (PRCA), myasthenia gravis (MG) and thymoma is reported. A 70-year-old woman presented with severe anemia. She had been diagnosed as having MG 8 years earlier and her symptoms were adequately controlled with ambenonium chloride. When she visited our hospital, her hematocrit was 13.7% with a hemoglobin concentration of 4.7 g/dl and her reticulocyte counts were persistently abnormal at 0.1%. Although both direct and indirect Coombs' tests were positive, there was no evidence of hemolysis. Routine screening tests for other etiologies of anemia were negative. Serological tests for anti-DNA and anti-acetylcholine receptor antibodies gave positive results. A bone marrow examination revealed severe erythroid hypoplasia. PRCA was diagnosed and the patient was treated with periodic transfusions. A lateral view chest roentgenogram and a computed tomography scan of the thorax showed the presence of an anterior mediastinal mass which was suspected to be thymoma. The patient underwent thymothymectomy and the tumor was diagnosed as a thymoma. Although the patient received no treatment for MG and PRCA after surgery, her hematological test results rapidly improved and she was discharged from the hospital on the 29th postoperative day. At that time, her hematocrit was 33.2%, her hemoglobin concentration was 10.0 g/dl, her peripheral reticulocyte level was 1.8% and her left partial ptosis had improved. She is doing well, 9 months after surgery. For a patient to remain in remission without treatment for PRCA and MG after thymothymectomy is extremely rare.

Entities:  

Mesh:

Year:  1998        PMID: 9861237     DOI: 10.1093/jjco/28.11.696

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

1.  Myasthenia gravis and pure red cell aplasia: a rare association.

Authors:  Riya Balikar; Neelam Narendra Redkar; Meenakshi Amit Patil; Sunil Pawar
Journal:  BMJ Case Rep       Date:  2013-02-14

2.  Triad of thymoma, myasthenia gravis and pure red cell aplasia combined with Sjögren's syndrome.

Authors:  Koichi Fujiu; Ryuzo Kanno; Yutaka Shio; Jyun Ohsugi; Yoshihiro Nozawa; Mitsukazu Gotoh
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-07

3.  Isoniazid-triggered pure red cell aplasia in systemic lupus erythematosus complicated with myasthenia gravis.

Authors:  Hideki Nakamura; Akitomo Okada; Atsushi Kawakami; Satoshi Yamasaki; Hiroaki Ida; Masakatsu Motomura; Daisuke Imanishi; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2009-08-25       Impact factor: 2.631

4.  Pure red cell aplasia and myasthenia gravis: a patient having both autoimmune conditions in the absence of thymoma.

Authors:  Annelise Aquilina; David James Camilleri; Josanne Aquilina
Journal:  BMJ Case Rep       Date:  2017-09-11

5.  Immunological system status and the appearance of respiratory system disturbances in thymectomized patients.

Authors:  Paweł Krawczyk; Marta Adamczyk-Korbel; Robert Kieszko; Elzbieta Korobowicz; Janusz Milanowski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007 Jan-Feb       Impact factor: 4.291

6.  Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature.

Authors:  Yasuyuki Saito; Yuri Sawada; Yasuhiko Koga; Noriaki Sunaga; Yusuke Tsukagoshi; Yoshimasa Hachisu; Takashi Osaki; Reiko Sakurai; Kyoichi Kaira; Akihiro Ono; Ken Sato; Hiromi Koiso; Tetsunari Oyama; Takeshi Hisada; Masanobu Yamada
Journal:  Intern Med       Date:  2017-09-15       Impact factor: 1.271

7.  Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin.

Authors:  Atsushi Isoda; Yuri Miyazawa; Kenichi Tahara; Masahiro Mihara; Akio Saito; Morio Matsumoto; Morio Sawamura
Journal:  Intern Med       Date:  2020-05-08       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.